In a report released today, Evan Seigerman from Credit Suisse maintained a Hold rating on Galera Therapeutics (GRTX – Research Report), with a price target of $8.00. The company’s shares closed last Wednesday at $7.66, close to its 52-week low
Get your FREE copy of this special report hightlighting 10 stock recommendations from the very best Wall Street Analysts.
Thank you for your submission!TipRanks special report will be sent to you shortly.